SOMERSET, N.J., Dec. 12, 2019 /PRNewswire-PRWeb/ -- Catalent, a global leader in clinical supply services, today announced the launch of its new CTSuccess™ clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.
The CTSuccess service uses Catalent's proprietary StartScore™ evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics. The StartScore model was developed by the company's in-house supply chain experts based on actual performance data. The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses.
"No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise," commented Kristen Devito, Global Director, Catalent Clinical Supply Services. "Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end."
Catalent's clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.
To find out more about Catalent's clinical supply services, visit http://www.clinical.catalent.com
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™